Online inquiry

IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8506MR)

This product GTTS-WQ8506MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGAL gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001114380.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3683
UniProt ID P20701
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8506MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7168MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ15287MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ6012MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ11583MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ4357MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ15323MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ9268MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ10968MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW